TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31684169

Group type: EXPERIMENTAL
Intervention: Mobile app-based stress-management program for four weeks
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 56
Study: 27271728

Group type: EXPERIMENTAL
Intervention: Embrace (integrated, person-centered primary care and support)
Number of subjects: 1456
Study: 25719617

Group type: EXPERIMENTAL
Intervention: Combination therapy (imipramine 75 mg/d + pregabalin 300 mg/d)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Imipramine (75 mg/d)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Pregabalin (300 mg/d)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Combination therapy
Number of subjects: 69
Study: 24733680

Group type: EXPERIMENTAL
Intervention: Illness Management and Recovery (IMR)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Weekly problem-solving group intervention
Number of subjects: 118
Study: 22282884

Group type: EXPERIMENTAL
Intervention: Cerebrolysin (30 mL daily for 10 days)
Number of subjects: 1070

Group type: COMPARATOR
Intervention: Placebo (saline solution, intravenous infusion for 10 days)
Number of subjects: 1070

Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Number of subjects: 1070

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1070
Study: 19773378

Group type: EXPERIMENTAL
Intervention: DeltaNp63 positive lesions
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: DeltaNp63 positive lesions, podoplanin positive lesions, and EIC
Number of subjects: 152
Study: 17498580

Group type: EXPERIMENTAL
Intervention: Implantable Loop Recorder (ILR) with 1-year monitoring (n = 26)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional strategy (24‐h Holter recording, 4-week ambulatory ECG monitoring, electrophysiological study) (n = 24)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Implantable Loop Recorder (ILR)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional strategy
Number of subjects: 50
Study: 15626943

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (HBV) plus measles vaccine
Number of subjects: 876

Group type: COMPARATOR
Intervention: Measles vaccine only
Number of subjects: 876

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (HBV)
Number of subjects: 876
Study: 11731687

Group type: COMPARATOR
Intervention: Hand-driven pump (control group)
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: CAPS 0.2 (computer-assisted dilatation at 0.2 bar/s)
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: CAPS 1.0 (computer-assisted dilatation at 1.0 bar/s)
Number of subjects: 454
Study: 9203566

Group type: EXPERIMENTAL
Intervention: Noradrenaline (6 x 10(‐9)‐6 x 10(‐6) M)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Phentolamine (1.24 x 10(‐4) M)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (isoosmolar saline)
Number of subjects: 7
Study: 7962303

Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 3630180

Group type: EXPERIMENTAL
Intervention: Ranitidine alone
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Ranitidine with bacampicillin
Number of subjects: 218

Group type: COMPARATOR
Intervention: Control group (normal mucosa)
Number of subjects: 218
Study: 31680054

Group type: EXPERIMENTAL
Intervention: DMLS
Number of subjects: 32

Group type: COMPARATOR
Intervention: CAST
Number of subjects: 32
Study: 29658810

Group type: EXPERIMENTAL
Intervention: Indacaterol/glycopyrronium (IND/GLY) or glycopyrronium (GLY)
Number of subjects: 4389

Group type: EXPERIMENTAL
Intervention: Decrease in wheeze on Day 7
Number of subjects: 4389

Group type: EXPERIMENTAL
Intervention: Nighttime symptoms and wheeze on Day 14
Number of subjects: 4389

Group type: EXPERIMENTAL
Intervention: Decrease in nighttime symptoms and wheeze on Day 7
Number of subjects: 4389

Group type: EXPERIMENTAL
Intervention: Nighttime symptoms, sputum and wheeze on Day 14
Number of subjects: 4389
Study: 27265388

Group type: EXPERIMENTAL
Intervention: Dark chocolate (>85% cocoa), 40 g/day for 2 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Milk chocolate (<35% cocoa), 40 g/day for 2 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: NASH patients compared to controls
Number of subjects: 38
Study: 24518826

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg·kg⁻¹ body mass)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 23875965

Group type: EXPERIMENTAL
Intervention: Estrogen (conjugated estrogen)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Estrogen (conjugated estrogen) plus progesterone (medroxyprogesterone acetate; MPA)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 62
Study: 20300126

Group type: EXPERIMENTAL
Intervention: HP-Guar group (27 patients)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Usual treatment group (21 patients)
Number of subjects: 48
Study: 18836927

Group type: EXPERIMENTAL
Intervention: Psychotherapeutic day treatment programme (5 months duration, including psychodynamic and cognitive-based therapy in group/individual settings)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 66
Study: 16651155

Group type: EXPERIMENTAL
Intervention: Local anesthesia with propofol infusion (LAP)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Spinal anesthesia (SA)
Number of subjects: 32
Study: 12796759

Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg
Number of subjects: 405

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 405
Study: 11040718

Group type: EXPERIMENTAL
Intervention: Prenatal education including information about newborn sickle cell screening
Number of subjects: 647

Group type: COMPARATOR
Intervention: No prenatal education about newborn sickle cell screening (control group)
Number of subjects: 647
Study: 9335416

Group type: EXPERIMENTAL
Intervention: Losartan 25 mg
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Losartan (combined with ACE inhibitor)
Number of subjects: 43
Study: 8409641

Group type: EXPERIMENTAL
Intervention: 1 alpha‐OH‐D3 (1.0 micrograms/day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (non-treated)
Number of subjects: 19
Study: 3021083

Group type: EXPERIMENTAL
Intervention: Clonidine hydrochloride (alpha 2‐adrenergic receptor agonist)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Yohimbine (alpha 2‐adrenergic receptor antagonist)
Number of subjects: 47
Study: 30665850

Group type: EXPERIMENTAL
Intervention: Continuous bilateral ESPB (0.25 mL/kg/side of ropivacaine 0.5%)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (IV morphine, 0.5 mg/h and IV nefopam, 100 mg/24 h)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Continuous bilateral ESPB
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 67
Study: 27699819

Group type: EXPERIMENTAL
Intervention: PSA growth curve model with a threshold of 0.37 ng/ml/year
Number of subjects: 68330

Group type: EXPERIMENTAL
Intervention: PSA growth curve model with a threshold of 0.99 ng/ml/year in African-American men (AA)
Number of subjects: 68330

Group type: EXPERIMENTAL
Intervention: PSA rate
Number of subjects: 68330
Study: 26145824

Group type: EXPERIMENTAL
Intervention: DTI-incorporated neuronavigation during surgery (24 patients)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Surgery without neuronavigation (22 patients)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both groups (DTI and control)
Number of subjects: 46
Study: 23315904

Group type: COMPARATOR
Intervention: BMS
Number of subjects: 2013

Group type: COMPARATOR
Intervention: PES
Number of subjects: 2013

Group type: COMPARATOR
Intervention: EES
Number of subjects: 2013

Group type: COMPARATOR
Intervention: ZES-S
Number of subjects: 2013
Study: 21273209

Group type: EXPERIMENTAL
Intervention: Younger group (mean age 25 ± 6 years)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Older group (mean age 64 ± 4 years)
Number of subjects: 60
Study: 19172243

Group type: EXPERIMENTAL
Intervention: Trientine (600 mg orally twice daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 16179401

Group type: EXPERIMENTAL
Intervention: Sprint training for 7 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 15
Study: 15488969

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine solution
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 30
Study: 11178766

Group type: EXPERIMENTAL
Intervention: Laparoscopic esophagogastric placement (EGP)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Laparoscopic retrogastric placement (RGP)
Number of subjects: 101
Study: 9494441

Group type: EXPERIMENTAL
Intervention: Warning label
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Information label
Number of subjects: 0

Group type: COMPARATOR
Intervention: No label
Number of subjects: 0
Study: 7755459

Group type: EXPERIMENTAL
Intervention: ACE inhibitor (quinapril 20 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3291439

Group type: EXPERIMENTAL
Intervention: 0.05% clobetasol‐17‐propionate (group A)
Number of subjects: 21

Group type: COMPARATOR
Intervention: 0.25% fluocortolone trimethyl acetate (group B)
Number of subjects: 21

Group type: COMPARATOR
Intervention: 0.25% fluocortolone trimethyl acetate + 0.25% fluocortolone capronate (group C)
Number of subjects: 21
Study: 1539143

Group type: EXPERIMENTAL
Intervention: Prophylactic digoxin
Number of subjects: 111

Group type: COMPARATOR
Intervention: No prophylactic digoxin (Control)
Number of subjects: 111
Study: 332089

Group type: EXPERIMENTAL
Intervention: Halcinonide cream
Number of subjects: 44

Group type: COMPARATOR
Intervention: Betamethasone valerate cream
Number of subjects: 44
Study: 31356721

Group type: EXPERIMENTAL
Intervention: High Ligation (HL)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Central Vascular Ligation (CVL)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Preoperative imaging for CVL
Number of subjects: 197
Study: 31063408

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 28532891

Group type: EXPERIMENTAL
Intervention: Integrated Myofascial Techniques (IMT)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Kinesio Tape (KT)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sham TENS (Control)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Pain Pressure Threshold (PPT)
Number of subjects: 44
Study: 26500862

Group type: EXPERIMENTAL
Intervention: Narrowband UVB (NBUVB) phototherapy at a fixed dose of 250 mJ/cm² three times a week for 4 weeks
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Narrowband UVB (NBUVB) phototherapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (no treatment)
Number of subjects: 100
Study: 23509322

Group type: EXPERIMENTAL
Intervention: Lapatinib plus paclitaxel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus paclitaxel
Number of subjects: 0
Study: 21692253

Group type: EXPERIMENTAL
Intervention: General anesthesia with preincisional paravertebral nerve block
Number of subjects: 40

Group type: COMPARATOR
Intervention: General anesthesia alone
Number of subjects: 40
Study: 19361782

Group type: EXPERIMENTAL
Intervention: Cognitive Recovery Intervention (CRI)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 66
Study: 16669305

Group type: EXPERIMENTAL
Intervention: Weekly ultrasound combined with standard care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 15606390

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (5‐aminlevulinic acid 30 mg/kg and red light)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Argon plasma coagulation (administered at a power setting of 65 W)
Number of subjects: 68
Study: 11685183

Group type: EXPERIMENTAL
Intervention: J&J Crown stent
Number of subjects: 203

Group type: COMPARATOR
Intervention: NIR stent
Number of subjects: 203
Study: 9676024

Group type: EXPERIMENTAL
Intervention: Filgrastim
Number of subjects: 42

Group type: COMPARATOR
Intervention: Molgramostim
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Filgrastim and Molgramostim
Number of subjects: 42
Study: 8742796

Group type: EXPERIMENTAL
Intervention: DMT (naturally occurring short‐acting hallucinogen), dosage and duration not specified
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2650751

Group type: EXPERIMENTAL
Intervention: Wagner‐Nelson (WN) method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hendeles‐Weinberger modification of the WN (HW)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Asymptotic WN (AWN) method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonlinear regression (NL) method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonlinear regression on cumulative sum of AUCs (AUCNL)
Number of subjects: 0
Study: 31992604

Group type: EXPERIMENTAL
Intervention: Telehealthcare solution (Telekit with tablet, digital blood pressure monitor, and scale)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Telehealthcare solution
Number of subjects: 274

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 274
Study: 31199103

Group type: EXPERIMENTAL
Intervention: Kinesio Taping (KT)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (regular rehabilitation)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Between-group comparison
Number of subjects: 31
Study: 28075499

Group type: EXPERIMENTAL
Intervention: Remote ischemic postconditioning applied to the arm
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Remote ischemic postconditioning applied to the thigh
Number of subjects: 360

Group type: COMPARATOR
Intervention: Control group (20 mm Hg to the arm)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Remote ischemic postconditioning (arm or thigh)
Number of subjects: 360
Study: 26636278

Group type: EXPERIMENTAL
Intervention: Strength training with superimposed EMS (S+E)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Strength training without EMS (S)
Number of subjects: 20
Study: 23219699

Group type: EXPERIMENTAL
Intervention: Exposure to misinformation (misleading photograph)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Misinformation introduced after the event
Number of subjects: 800
Study: 25729661

Group type: EXPERIMENTAL
Intervention: BoNT‐A (40 Ipsen units per injection)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 50
Study: 18155484

Group type: EXPERIMENTAL
Intervention: Buccal infiltrations (BI) with 1.7 mL of 4% articaine with 1:100,000 adrenaline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inferior alveolar nerve blocks (IANB)
Number of subjects: 0
Study: 16686875

Group type: EXPERIMENTAL
Intervention: Female Narrator Voice
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Female-stereotyped narratives
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Narratives rated as Plausible
Number of subjects: 33
Study: 14595085

Group type: EXPERIMENTAL
Intervention: Low-GI breakfast
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Low-GI breakfast with added sucrose
Number of subjects: 37

Group type: COMPARATOR
Intervention: High-GI breakfast
Number of subjects: 37

Group type: COMPARATOR
Intervention: Habitual breakfast
Number of subjects: 37
Study: 11353990

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 800 mg/day with interferon
Number of subjects: 18

Group type: COMPARATOR
Intervention: Interferon alone
Number of subjects: 18
Study: 9610579

Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg/day)
Number of subjects: 3270

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3270
Study: 7761010

Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.01 mg/kg) with a primer of 0.003 mg/kg of buprenorphine
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.01 mg/kg) with a primer of 0.5 mg/kg of ketorolac
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (Buprenorphine only, no primer)
Number of subjects: 300
Study: 3186087

Group type: EXPERIMENTAL
Intervention: Intrapartum treatment with ampicillin and gentamicin during labor
Number of subjects: 45

Group type: COMPARATOR
Intervention: Postpartum treatment
Number of subjects: 45
Study: 31448420

Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen low dose
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen high dose
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study: 29969928

Group type: EXPERIMENTAL
Intervention: Tiotropium as add-on therapy to inhaled corticosteroids
Number of subjects: 536

Group type: COMPARATOR
Intervention: Long acting beta agonist as add-on therapy to inhaled corticosteroids
Number of subjects: 536
Study: 28935773

Group type: EXPERIMENTAL
Intervention: Gemcitabine/nab-paclitaxel plus apatorsen
Number of subjects: 132

Group type: COMPARATOR
Intervention: Gemcitabine/nab-paclitaxel plus placebo
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 132
Study: 27473445

Group type: EXPERIMENTAL
Intervention: High-intensity low-volume training (HIT)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 62
Study: 25275069

Group type: EXPERIMENTAL
Intervention: Daily erlotinib for 12 consecutive days prior to docetaxel (Arm A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Docetaxel followed by daily erlotinib (Arm B)
Number of subjects: 50
Study: 22934861

Group type: EXPERIMENTAL
Intervention: Preoperative education
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 19605762

Group type: EXPERIMENTAL
Intervention: Endurance training for 3 months
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (no endurance training)
Number of subjects: 17
Study: 17488457

Group type: EXPERIMENTAL
Intervention: Blood glucose clamped at 5 mmol/l
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Blood glucose clamped at 15 mmol/l
Number of subjects: 9
Study: 15337134

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) 500 mg b.d., titrated to a maximum of 3 g/day
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) for patients with Lennox-Gastaut syndrome (LGS)
Number of subjects: 10
Study: 16894771

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging and 1H MR spectroscopy
Number of subjects: 0
Study: 10463847

Group type: EXPERIMENTAL
Intervention: Myoclonic Astatic Epilepsy (MAE) - Group 1 (37 children)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Myoclonic Astatic Epilepsy (MAE) - Group 2 (18 children)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Lennox-Gastaut Syndrome - Group 3 (11 children)
Number of subjects: 72
Study: 8903618

Group type: EXPERIMENTAL
Intervention: ACE inhibitors monotherapy
Number of subjects: 125
Study: 11527126

Group type: EXPERIMENTAL
Intervention: Bisoprolol 10 mg o.d.
Number of subjects: 41

Group type: COMPARATOR
Intervention: Chlorthalidone 50 mg o.d.
Number of subjects: 41
Study: 358381

Group type: EXPERIMENTAL
Intervention: Norephedrine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 31747385

Group type: EXPERIMENTAL
Intervention: Educational video
Number of subjects: 289

Group type: COMPARATOR
Intervention: Written information sheet (Control)
Number of subjects: 289
Study: 30773862

Group type: EXPERIMENTAL
Intervention: Deep acupuncture of CV22 + rehabilitation training
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional acupuncture + swallowing rehabilitation training
Number of subjects: 70
Study: 28067701

Group type: EXPERIMENTAL
Intervention: Pharmacologic preconditioning with sevoflurane
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Pharmacologic postconditioning with sevoflurane
Number of subjects: 129

Group type: COMPARATOR
Intervention: Total intravenous anesthesia (control)
Number of subjects: 129
Study: 25968121

Group type: EXPERIMENTAL
Intervention: Three-part alcohol brief intervention (BI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention control (AC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention control with limited assessment (AC)
Number of subjects: 0
Study: 23407853

Group type: EXPERIMENTAL
Intervention: Sitagliptin monotherapy (100 mg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Atorvastatin (40 mg for 5 days) + Sitagliptin (100 mg on day 5)
Number of subjects: 29
Study: 19939876

Group type: EXPERIMENTAL
Intervention: Tyrosine/phenylalanine depletion (TPD)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 17
Study: 19732668

Group type: EXPERIMENTAL
Intervention: DMAX‐2000
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Haas
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: MAX‐2000
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control
Number of subjects: 65
Study: 17762445

Group type: EXPERIMENTAL
Intervention: Centrum Silver (multivitamins)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 15565033

Group type: EXPERIMENTAL
Intervention: 5-mL vacuum collection tubes
Number of subjects: 12

Group type: COMPARATOR
Intervention: 10-mL vacuum collection tubes
Number of subjects: 12
Study: 11487548

Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg/d for 1 week
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 9851896

Group type: EXPERIMENTAL
Intervention: C282Y mutation homozygosity in patients with grade 3 or 4 hepatic iron deposition
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: C282Y mutation homozygosity in patients with <3+ iron deposition
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: C282Y and H63D mutation heterozygosity
Number of subjects: 78

Group type: COMPARATOR
Intervention: C282Y mutation heterozygosity in control individuals
Number of subjects: 78

Group type: COMPARATOR
Intervention: H63D mutation heterozygosity in control individuals
Number of subjects: 78
Study: 9130897

Group type: EXPERIMENTAL
Intervention: Assisted hatching
Number of subjects: 49
Study: 1928474

Group type: EXPERIMENTAL
Intervention: Fluoxetine (up to 80 mg/day)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21